Suki closes $90M Series E to build beyond the clinical note

Suki listens during medical appointments and turns the conversation into draft notes, patient instructions and orders that can move into a clinician’s electronic health record. The Redwood City company has closed a $90 million Series E, Inc reported on October 12 after interviewing founder and CEO Punit Soni. The financing backs software intended to take more administrative work away from physicians.

During a visit, clinicians can combine ambient capture with dictation and voice commands. Suki says the system formats notes for more than 100 specialties, stages orders and suggests billing codes before a note is closed. Its bidirectional integrations with Epic, Oracle Health, athenahealth and MEDITECH are meant to keep that work inside the record system instead of requiring copy-and-paste between applications.

The same product reaches beyond the appointment itself. It can summarize a chart and answer questions about patient history beforehand, then capture diagnoses and recommend ICD-10, E&M and HCC codes afterward. Documentation is the entry point to Suki’s clinical and billing workflows, rather than the whole product.

Suki distributes that technology two ways. Soni told Inc that the main application is used by more than 450 health-care organizations; the company also licenses its underlying AI to more than 30 health-tech partners that build it into their own products. Both adoption figures are company-supplied.

Zoom Ventures, Philips Ventures, Healthier Capital and Hercules Capital were among the Series E backers, with Crosslink Capital, Venrock, Flare Capital Partners and Hedosophia also participating, according to Inc. Suki’s previous financing was a $70 million Series D in October 2024. The company did not disclose an updated post-money valuation for the latest round.

Soni said Suki will use the new capital to expand its ambient clinical-intelligence capabilities and build agents for work that follows a visit, including referrals and scheduling. Those tasks remain part of the development plan; Inc described the current product as handling notes, revenue-cycle work, operational workflows and clinical guidance. Suki also told the publication that revenue doubled in 2025 and was on track to do so again in 2026.